You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Drugs in MeSH Category Ganglionic Blockers


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Ayerst ANSOLYSEN pentolinium tartrate INJECTABLE;INJECTION 009372-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Targacept INVERSINE mecamylamine hydrochloride TABLET;ORAL 010251-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Roche ARFONAD trimethaphan camsylate INJECTABLE;INJECTION 008983-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Lgm Pharma MECAMYLAMINE HYDROCHLORIDE mecamylamine hydrochloride TABLET;ORAL 204054-001 Mar 19, 2013 RX No Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Ganglionic Blockers Market Analysis and Financial Projection

Ganglionic blockers, which inhibit autonomic ganglia transmission by antagonizing nicotinic receptors, occupy a niche yet evolving position in both therapeutic use and intellectual property landscapes. Here's an analysis of their market dynamics and patent environment:


Therapeutic and Market Dynamics

Current Clinical Use:

  • Ganglionic blockers like trimethaphan and mecamylamine are primarily used for controlled hypotension during surgery (e.g., aortic dissection) and hypertensive emergencies[1][7]. Their broad autonomic effects limit routine use, with preference now given to more selective agents[6][15].

Market Growth Drivers:

  • The nicotinic antagonists market (including ganglionic blockers) is projected to grow at a 3.75% CAGR through 2031, driven by surgical demand and advancements in anesthesia[17].
  • Key players include Aventis Pharma, GlaxoSmithKline, and Organon, focusing on neuromuscular blockade applications[17].

Challenges:

  • Limited awareness of ganglionic blockers’ benefits and strict regulatory hurdles restrict market expansion[17].
  • Older drugs like hexamethonium and pentolinium face competition from newer antihypertensives with fewer side effects[2][7].

Patent Landscape

Expired Patents and Generics:

  • Most ganglionic blockers (e.g., mecamylamine, trimethaphan) are off-patent, leading to widespread generic availability[7][10].
  • Hexamethonium, once a first-line antihypertensive, is now largely obsolete due to adverse effects and lack of patent protection[2][7].

Emerging Innovations:

  • Recent patents focus on alternative applications, such as galantamine for retinal ganglion cell protection[12] and methods for nerve conduction blocking[16]. These highlight shifts toward niche therapeutic areas rather than traditional uses.

Legislative Pressures:

  • Proposed laws like the Affordable Prescriptions for Patients Act aim to limit "patent thickets" for biologics[4][9]. While ganglionic blockers (small-molecule drugs) are less affected, the broader push for generic/biosimilar competition could indirectly pressure pricing strategies[4][10].

Competitive Outlook

  • Generic dominance: With expired patents, generics dominate the market, reducing revenue for originator companies[7][10].
  • Pipeline gaps: Limited R&D investment exists for new ganglionic blockers, though repurposing efforts (e.g., neuroprotection) show promise[12][14].
  • Regional trends: The Asia-Pacific market is growing due to rising surgical volumes and increased tobacco-related disease burden[17].

Key Takeaways

  1. Ganglionic blockers remain clinically relevant in emergencies but face competition from targeted therapies.
  2. The market relies on generics, with innovation focusing on novel applications rather than new chemical entities.
  3. Legislative changes targeting biologics have minimal direct impact, but broader patent reforms could influence pricing and accessibility.

"The first effective antihypertensive drug, hexamethonium, paved the way for modern cardiovascular therapies but now serves as a reminder of the balance between efficacy and side effects."[2][7]

While the ganglionic blocker market is stagnant, its legacy persists in shaping emergency care and niche therapeutic areas. Future growth may hinge on repurposing strategies and regulatory landscapes favoring affordability over exclusivity.

References

  1. https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Ganglionic_blockers/
  2. https://en.wikipedia.org/wiki/Ganglionic_blocker
  3. https://pubmed.ncbi.nlm.nih.gov/27000/
  4. https://www.lifescienceleader.com/doc/trends-in-proposed-laws-aimed-at-drug-patents-0001
  5. https://mdpi-res.com/bookfiles/book/3230/Opioids_and_Their_Receptors.pdf?v=1742176994
  6. https://www.wikidoc.org/index.php/Ganglionic_blocker
  7. https://go.drugbank.com/categories/DBCAT001047
  8. https://www.ncbi.nlm.nih.gov/mesh/68010393
  9. https://jlsp.law.columbia.edu/wp-content/blogs.dir/213/files/2021/11/Vol.-54-Geaghan-Breiner.pdf
  10. https://biopatrika.com/industry/pharma-biopharma/ten-high-value-drugs-losing-patent-protection-in-2025/
  11. https://www.iqvia.com/blogs/2023/10/finding-the-growth-engines-of-the-endocrine
  12. https://patents.google.com/patent/US20100168081A1/en
  13. https://www.fiercepharma.com/pharma/closer-look-pharmas-top-patent-losses-2025
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC9720821/
  15. https://meshb-prev.nlm.nih.gov/record/ui?name=Ganglionic+Blockers
  16. https://patents.google.com/patent/US9358374B2/en
  17. https://www.growthplusreports.com/report/nicotinic-antagonists-market/8998
  18. https://pubmed.ncbi.nlm.nih.gov/29010/
Last updated: 2025-03-24

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.